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Monitoring of minimal residual disease (MRD) allo-SCT by
quantitative real-time PCR (qRT-PCR) of rearranged Ig- and
TCR-genes may highlight patients with highest risk for
relapse.
In the prospective phase 3 trial ALL-SCT-BFM-2003
(recruitment period 09/2003 to 09/2011; time point of
analysis May 2013), MRD was assessed in bone marrow
immediately on days +30, +60, +100, +200 and +365 post
transplantation in 115 patients. Of these, 48 were male and
67 were female patients. All received a myeloablative con-
ditioning regimenwith TBI and VP 16. Patients received their
transplant in CR2 (n¼94), CR3 (n¼21), CR4 (n¼1) or NR
(n¼2). The transplantations were performed with bone
marrow frommatched sibling donors (MSD, n¼23), matched
unrelated donors (MUD, n¼71) or with T-cell depleted stem
cells from mismatched donors (MMD, n¼21). Fifty-four pa-
tients were younger than 10 and 61 patients were older than
10 years at the time of transplant.
Standardized quantiﬁcation of MRD was performed accord-
ing to the guidelines of the Euro-MRD-Group and MRD re-
sults were not released to the clinicians.
The total group of patients showed a pEFS of 0.520.10;
cumulative incidence of relapse (CIR) and cumulative
incidence of treatment related mortality (CI TRM) was
0.410.11 and 0.190.09, respectively. In 76 patients, MRD
could also be assessed prior to transplant: patients who
were MRD negative (n¼41) had a three year pEFS of
0.620.04, patients with a MRD load of <10E-3 (n¼28) of
0.490.14 and none of the patients who were MRD posi-
tive >1E-3 survived their disease. MRD values post
transplant were analyzed as time-dependent covariates.
When analyzed either for the different time points or for
the highest MRD value post transplant, MRD results had
always signiﬁcant inﬂuence on survival. Taken the highest
MRD value post transplant, probabilities of pEFS and CIR
were 0.650.11 and 0.230.09 for MRD negative patients
(n¼72), 0.360.18 resp. 0.75 0.18 for patients with MRD
<10-3 (n¼36) compared to 0.000.0 and 1.00.0 in pa-
tients who developed MRD 10-3leukemic cells (n¼07)
(pEFS, P<0.0001; CIR, P<0.0001). In multivariate cox
regression analysis, MRD prior and post transplantation,
as well as indication for SCT, signiﬁcantly inﬂuenced the
probability of survival. It is noteworthy, that all patients
who developed a MRD load of >10E-3 at any time after
transplant ﬁnally developed relapse and died. However,
49% of patients who became MRD positive <10E-3 did not
necessarily develop frank relapse. Here, dynamic evolu-
tion needs to be considered as 9/15 patients with an MRD
load of <10E-3 at day 200 survived. However, if MRD was
not cleared by day 365 all patients ﬁnally relapsed.Assessment of MRD post transplant allows the identiﬁcation
of patients with impending relapse. All patients who devel-
oped MRD >10E-3 at any time post transplant ﬁnally
relapsed. Therefore, MRD may serve as an endpoint for
further pre-emptive therapies.96
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This study aims to describe outcomes of allogeneic cord
blood transplantation (CBT) in leukodystrophies (LD). LD are
rare inborn errors of metabolism in which the brain myelin
is primarily affected, characterized by rapid neurological
deterioration. Hematopoietic stem cell transplantation
(HSCT) can halt disease progression for selected leukodys-
trophies, including adrenoleukodystrophy (ALD), Krabbe
disease (globoid cell leukodystrophy) and metachromatic
leukodystrophy (MLD). Unrelated cord blood has the
advantage of being rapidly available.
All patients undergoing CBT for LD in EBMT centers between
1996 and 2012 were included. HSCT data were collected
from the EUROCORD database. An additional questionnaire
on disease-speciﬁc clinical outcomes was sent to
Table 1. HSCT outcomes in children with hypodiploid ALL at 5 years
DFS % (range) OS % (range) Relapse% (range) TRM% (range)
<———————————————————————5 year estimates———————————————————————>
All patients 51 (40-62) 56 (44-67) 27 (18-38) 22 (14-32)
Patients in CR1 55 (40-70) 58 (43-72) 26 (14-40) 20 (9-33)
CR1 patients with 43 chromosomes 47 (29-66) 50 (32-69) 30 (15-47) 23 (9-41)
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calculate overall survival (OS) and cumulative incidence
methods for secondary outcomes, including neutrophil and
platelet engraftment, incidence of graft-versus-host disease
(GvHD) and disease-speciﬁc characteristics at most recent
follow-up. The two-sided log-rank test was used for univar-
iate comparisons.
Seventy patients (31 ALD, 5 Krabbe, 34 MLD) were available
for analysis, with a median age at transplant of 6.5 years.
Median follow-up for survivors was 46 months. OS at 4 years
was 60% (6%). Cumulative incidences of neutrophil and
platelet engraftment were 88% (4%) at day 60, and 73%
(6%) at day 180, resp. Acute-GvHD (grade II-IV) occurred in
16 patients (22% 5%) at day 100 and chronic-GvHD in 9
patients (13%5%). Out of the 24 patients who died, 18 (67%)
died of transplant-related causes and 6 (33%) died of disease
progression. Higher OS was seen in patients who had no or 1
HLA mismatch (OS 81%), compared to patients who received
a CBT with 2 HLA mismatches (OS 47%, p 0.02).
On 37 patients (53%), information on disease-speciﬁc char-
acteristics was available. OS among these patients was 68%
(8), which was not signiﬁcantly different from patients
without disease-speciﬁc information (p¼0,307). Nineteen
patients (51%) were asymptomatic at transplant, 14 (38%)
had mild disease and 4 (11%) were severely affected. Overall
survival was worse in patients with severe disease at trans-
plant; none of these 4 patients survived, versus 79% of mildly
affected and 76% of asymptomatic patients. At most recent
follow-up, disease status was stable in 15 (57.7%), had
improved in 2 (7.7%) and worsened in 9 (34.6%) surviving
patients. The majority of patients showed abnormalities on
MRI-scanning pre-HSCT (n¼25, 68%). In patients with
normal MRI-scans pre-transplant OS was 69%; in patients
with abnormal MRI-scans 75%.
In conclusion, we found an encouraging OS of 60% at 4 years,
with relatively low rates of GvHD. Use of a mismatched
donor (>1 HLA) negatively impacts survival. Data on clinical
characteristics suggest that OS is strongly inﬂuenced by
disease status at transplant.97
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chemotherapy despite intensive risk adapted treatment. A
case series of pediatric hypodiploid ALL (n¼139) with <45
chromosomes treated by 10 different national ALL study
groups (Nachman et al; 2007), reported an 8-year event free
survival (EFS) of 38.5% and overall survival (OS) of 49.8%.
Patients with fewer than 44 chromosomes fared signiﬁcantly
worse than those with 44 chromosomes (EFS of 30% vs. 52%,
p¼0.01). A similar report from the Medical Research Council
(MRC) included 226 children and adults treated with
chemotherapy (Harrison et al, 2004). Patients with 42-45
chromosomes (n¼153) had a 3 year survival of 66%
compared to 29% in those with 25-39 chromosomes.
We conducted a retrospective study of 78 children with hy-
podiploid ALL who underwent HSCT between 1990 and 2010
and reported to CIBMTR, to determine whether outcomes
might be improved with transplant.
Median age at HSCT was 10 years (range 3-18). Thirty nine
(50%) patients had  43 chromosomes, 12 (15%) had 44
chromosomes and 27 (35%) had 45 chromosomes. Forty
three (55%) patients were transplanted in CR1while 35 (45%)
were transplanted in CR2. Twenty nine patients (37%)
received a graft from a related donor, 34 (44%) an unrelated
donor and 15 (19%) cord blood. Demographics and transplant
characteristics were similar in those with chromosomes 43
or44 and those transplanted with early or late disease (CR1
or CR2 and beyond). All patients received a myeloablative
conditioning regimen.
Multivariate analysis conﬁrmed both disease status and
number of chromosomes were independently associated
with mortality; mortality risks were higher for transplants in
CR2 (HR 2.16, p¼0.05) and when chromosomes were <¼43
(HR 2.15, p¼0.05).The 5-year estimates of DFS, OS, relapse,
and treatment related mortality (TRM) for the entire group,
those in CR1 and for those in CR1with43 chromosomes are
shown in Table 1. In the group with 44 chromosomes
(n¼13), 3 patients died and 10 were alive at last contact (9
disease free and 1 with relapsed disease). Despite the
obvious limitation of small numbers of patients and the
retrospective nature of our study, our results suggest that
compared to historical results from chemotherapy only
treatment, pediatric patients with hypodiploid ALL, may
have improved outcomes when transplanted in CR1, and
beneﬁt may be most notable in those with 43 chromo-
somes.98
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